Ryutaro Uchi’s research while affiliated with National Hospital Organization Kyushu Cancer Center and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (3)


Fig. 3. Macroscopic and microscopic (HE staining) of the extracted metallic stent. Extreme granulation is observed in the lumen.
Removal of a Metallic Stent after 9 Years of Placement That Caused Tracheal Stenosis: A Rare Case Report
  • Article
  • Full-text available

February 2024

·

26 Reads

Case Reports in Oncology

Torahiko Nakashima

·

Koji Yamazaki

·

Ryutaro Uchi

·

b> Introduction: Metallic stents are widely used to prevent airway obstruction for tracheal stenosis caused by malignant diseases. Although their efficacy has been recognized, there is no established evidence surrounding their long-term safety. We report a case of airway stenosis caused by a metallic tracheal stent. Removal of the stent to secure the airway was difficult and extremely complicated. Case Presentation: A 50-year-old male suffering from dyspnea caused by malignant lymphoma (diffuse large B-cell lymphoma) of the thyroid gland was treated with a metallic tracheal stent. After remission of the lymphoma, stenosis of the stent lumen developed gradually, and the patient complained of dyspnea. Tracheostomy could not be performed due to the metallic stent. Since the patient was unable to intubate, the stent was removed under general anesthesia with partial percutaneous cardiopulmonary support 9 years after the stent placement. Conclusion: Otolaryngologists should be aware of the possibility of severe stenosis following the long-term placement of a metallic tracheal stent.

Download

Study on the treatment outcomes of advanced laryngeal and hypopharyngeal cancer with induction chemotherapy導入化学療法を行った進行喉頭・下咽頭癌の治療成績の検討

November 2023

·

1 Read

Japanese Journal of Head and Neck Cancer

·

Shingo Tamura

·

Rina Kitagawa

·

[...]

·

Torahiko Nakashima

Induction chemotherapy (ICT) of DTX+CDDP+5-FU (TPF) has been reported to be useful as pretreatment preceding standard CDDP combination chemoradiotherapy (CCRT) for head and neck cancer. However, ICT causes many adverse events, and its effectiveness is still controversial. We conducted a study on ICT followed by CCRT in 30 cases of advanced laryngeal and hypopharyngeal cancer with a desire for laryngeal preservation. We examined completion rates, success rates based on primary tumor (T) and neck lymph node (N) metastasis, prognosis, and laryngeal preservation. Nine cases had laryngeal cancer (Stage Ⅲ:4 cases, Stage Ⅳ:5 cases) and 21 cases had hypopharyngeal cancer (Stage Ⅲ:3 cases, Stage Ⅳ:18 cases). The completion rate of ICT (TPF 2 courses) was 93%, and the completion rate of ICT+CCRT was 82%. The success rate of ICT was T100%, N80%, and the success rate of ICT+CCRT was T97%, N92%. The two-year overall survival rate was 75%, and the two-year laryngeal preservation survival rate was 67%, indicating good results. From this study, it is considered that good completion and effects can be achieved with TPF-based ICT and CCRT by selecting cases and addressing adverse events.


Long term follow up of hearing loss after administration of cisplatin for head and neck cancer頭頸部癌に対するシスプラチン投与後の聴覚障害の長期観察: —Involvement as a Speech-Language-hearing therapist——言語聴覚士の関わり—

January 2023

Japanese Journal of Head and Neck Cancer

Chemoradiotherapy (CRT) with cisplatin is a standard treatment for head and neck cancer. However, it is known that administration of platinum agents (such as cisplatin and carboplatin) causes hearing impairment. In this study, pure tone audiometry was performed for 33 head and neck cancer patients who underwent CRT with cisplatin. Hearing tests were performed before the first dose of cisplatin, and at 3 months, 6 months, and 1 year after the first dose. As a result, 76% of the patients had hearing loss after 1 year. We also analyzed how the total cisplatin dose, age, sex, and smoking history were related to hearing impairment and found that there was no significant difference. Long-term follow-up revealed that many patients have hearing impairment after cancer treatment. Medical involvement including supportive care is required for a long period after CRT for head and neck cancer patients.